New patient survey highlights need for more action to help severe asthma patients gain control of their disease

NovartisNovartis announced the results of a new survey of 904 severe asthma patients, presented for the first time at the European Academy of Allergy and Clinical Immunology (EAACI) Congress[1]. Data from the 'Still Fighting for Breath' survey demonstrate that, despite the widespread availability of oral and inhaled treatments, asthma still places a huge burden on the personal and professional lives of those living with the disease in Europe.

The new survey revealed that high levels of uncontrolled disease still exist amongst adults and children with severe asthma. Asthma attacks (also known as exacerbations) were reported to be extremely common. Nearly three quarters (74%) of patients surveyed experienced an attack serious enough to have required treatment from a healthcare professional in the emergency room, ambulance or at home. Furthermore, almost a third (32%) of patients experienced three or more exacerbations during this time period. While a majority of patients (54%) experiencing an exacerbation physically recovered after treatment within 24 hours, these patients often remained psychologically affected for a prolonged period of time after the exacerbation, with almost a fifth of them (19%) reporting effects persisting over a week[1].

Importantly, this new research found a significant discrepancy between "perceived" versus "real life" asthma control. Specifically, nearly half (46%) of the patients surveyed had self-estimated themselves as being "controlled", which is a marked contrast to the 6% of patients that were actually deemed as "controlled" according to the Global Initiative for Asthma (GINA) clinical guidelines. This discrepancy may be a limiting factor in patients seeking support to control their condition.

"The results from this new survey are important as the data demonstrate that too many patients in Europe are living with the daily burden of uncontrolled severe asthma. As such, this patient population may be significantly under-served", said Professor Antonella Muraro, one of the authors of the survey. "More needs to be done and the first step is to bridge the gap between the perceptions of 'good' control vs reality, among people with asthma. We need to focus greater efforts on empowering and educating those living with asthma to fight for better outcomes and to help them achieve a life unrestricted by their condition."

In addition to revealing the high levels of uncontrolled disease, the survey also underscored the disruptive impact that living with severe asthma has on the lives of patients. Nearly nine out of ten patients reported that their condition impacted their daily living (88%) and 84% reported that it impacted physical activities, with almost all patients (97%) reporting it disturbed their sleep. Significantly, half of the patients surveyed believe their professional lives are negatively impacted by their condition.

In response to the survey findings Novartis is launching a new patient engagement program, entitled Billion Breaths. The program will encourage people to set activity goals and provide advice and support to help them achieve a life less restricted by asthma [https://www.youtube.com/watch?v=kniyOgnpQr4 (link is external)].

About the asthma impact study in Europe
The study enrolled 904 adult patients (>=18 years) and children (6-17 years old) suffering from severe persistent asthma. It spanned several countries, including the United Kingdom (n=190), Germany (n=170), France (n=170, Italy (n=116), Spain (n=115) and Portugal (n=30).

Data were collected through an online survey between July 12 and October 31 2016. Data for adolescent and pediatric patients were obtained through caregivers. Collection and analysis of all data was completed by GFK Health on behalf of Novartis.

The severe asthmatic patients in this survey were diagnosed by respiratory physicians (38%), general practitioners (33%), allergists (23%) and pediatricians (5%). On average, adults were diagnosed with the disease 15 years ago, adolescents seven years old and pediatrics three years ago. According to the patients' understanding 49% considered themselves to have non-allergic asthma (no additional tests were performed).

About asthma
Asthma is a global health problem[2] affecting an estimated 300 million people worldwide[3]. It is a common long-term condition that can cause coughing, wheezing, chest tightness and breathlessness.

There is no cure for asthma and treatment focuses on symptom relief[3]. Asthma symptoms can either gradually or suddenly become worse. This is commonly referred to as an "asthma attack" or "exacerbation". Severe exacerbations may require hospital treatment and can be life- threatening[4]. However, when appropriate treatment is instituted, asthma can be controlled without symptoms.

There are many different types of asthma. Severe asthma is a specific form of asthma that requires specialist care and support. It affects approximately 5% of people with the condition. A patient with severe asthma may have breathing difficulties and is also at risk of serious exacerbations[5].

Approximately 87% of severe asthma patients have taken oral corticosteroids (OCS), for a reported average period of 20 days in the last six months[1]. The updated 2017 GINA guidelines for asthma management state that patients should be provided with written guidance on when/how to commence OCS treatment, typically a short course (40mg/day for 5-7 days), and should also be advised of the potential side effects that may occur when taking OCS[2].

About Novartis
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has leading positions globally in each of these areas. In 2016, the Group achieved net sales of USD 48.5 billion, while R&D throughout the Group amounted to approximately USD 9.0 billion. Novartis Group companies employ approximately 118,000 full-time-equivalent associates. Novartis products are sold in approximately 155 countries around the world.

1. Katsaounou P, Conde L G, Kroegel C et al. The challenges of living with severe asthma in Europe. Abstract #858 presented at EACCI Congress 2017
2. Global Strategy for Asthma Management and Prevention (2017). http://ginasthma.org/2017-gina-report-global-strategy-for-asthma-management-and-prevention/ [Accessed March 2017]
3. World Health Organization. Global surveillance, prevention and control of chronic respiratory diseases: a comprehensive approach, 2007. http://www.who.int/gard/publications/GARD%20Book%202007.pdf. [Accessed April 2017]
4. NHS Choices - Asthma. http://www.nhs.uk/conditions/Asthma/Pages/Introduction.aspx [Accessed April 2017]
5. Asthma UK, Severe asthma and difficult to control asthma. https://www.asthma.org.uk/advice/understanding-asthma/types/severe-asthma/ [Accessed March 2017]

Most Popular Now

Scientists identify synthetic mini-antibody to com…

The ability of SARS-CoV-2 to infect cells depends on interactions between the viral spike protein and the human cell surface protein ACE2. To enable the virus to hook ont...

New drug candidate for the treatment of COVID-19

Researchers from the University of Kent, the Goethe-University in Frankfurt am Main (Germany), and the Hannover Medical School (Germany) have identified a drug with the p...

Cancer treatment could be replicated for COVID-19

Beta-blockers could potentially be used to treat COVID-19, according to a new international study by Italian and Australian scientists. University of South Australia c...

European Commission approves contract with BioNTec…

Today, the European Commission approved a fourth contract with pharmaceutical companies BioNTech and Pfizer, which provides for the initial purchase of 200 million doses ...

Lilly's neutralizing antibody bamlanivimab (LY-CoV…

The U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for Eli Lilly and Company's (NYSE: LLY) investigational neutralizing antibody bamlan...

Medicago and GSK announce start of Phase 2/3 clini…

Medicago, a biopharmaceutical company headquartered in Quebec City, and GSK have announced the start of Phase 2/3 clinical trials of its plant-derived vaccine candidate f...

Pre-existing coronavirus antibodies could help pro…

Researchers at the Francis Crick Institute and University College London have found that some antibodies, created by the immune system during infection with common cold c...

Swissmedic begins rolling review of Moderna's mRNA…

Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for...

Fluvoxamine may prevent serious illness in COVID-1…

In a preliminary study of COVID-19 patients with mild-to-moderate disease who were attempting to recover in their homes, researchers at Washington University School of Me...

Remdesivir for COVID-19: FDA approved but still un…

The United States has become the epicenter of the world in the ever increasing pandemic of COVID-19. While public health prevention strategies of social distancing, crowd...

The Sputnik V COVID-19 vaccine efficacy amounted t…

The National Research Center for Epidemiology and Microbiology named after N.F. Gamaleya of the Ministry of Health of the Russian Federation (Gamaleya Center) and the Rus...

Novartis provides update on CAN-COVID trial in hos…

Novartis today announced new data from an interim analysis for the randomized, double-blind, placebo-controlled CAN-COVID trial evaluating the efficacy and safety of cana...